Durable immunity after recovery from symptomatic COVID-19 was reported in a cohort of 188 COVID-19 cases, mostly with mild disease, with ~95% of subjects presenting with SARS-CoV-2 specific antibodies, memory B cells, CD4+ and CD8+ T cells 6 months after the initial infection. This evidence concerns the gene CD8A and COVID-19.